The FDA on Tuesday gave Servier’s Tibsovo (ivosidenib tablets) an additional indication, allowing its use in patients with relapsed or refractory myelodysplastic syndromes carrying a susceptible IDH1 mutation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,